Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dishman Pharma Gains 5%; BSE HEALTHCARE Index Down 0.1%
Tue, 2 Jul 12:6

Dishman Pharma Gains 5%; BSE HEALTHCARE Index Down 0.1%Image source: Sakorn BernardaSv/www.istockphoto.com

Dishman Pharma share price has zoomed 5% and is presently trading at Rs 301.1.

Meanwhile, the BSE HEALTHCARE index is at 37,208.4 (down 0.1%).

Among the top gainers in the BSE HEALTHCARE index today are AARTI DRUGS (up 4.4%) and ALEMBIC PHARMA (up 4.2%).

MAX HEALTHCARE INSTITUTE (down 3.4%) and KIMS (down 1.4%) are among the top losers today.

Over the last one year, Dishman Pharma has moved up from Rs 153.3 to Rs 301.1, registering a gain of Rs 147.8 (up 96.4%).

On the other hand, the BSE HEALTHCARE index has moved up from 25,634.3 to 37,208.4, registering a gain of 45.2% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 85.2%), Cadila Healthcare (up 83.7%) and GSK Pharma (up 83.4%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 79,541.5 (up 0.1%).

The top gainers among the BSE Sensex today are Infosys (up 2.4%) and L&T (up 2.2%). The most traded stocks in the BSE Sensex are Tata Steel and SBI.

In the meantime, NSE Nifty is at 24,161.3 (up 0.1%). Wipro and L&T are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 63,915.4 to 79,541.5, registering a gain of 15,626.1 points (up 24.4%).

Dishman Pharma Financial Update...

Dishman Pharma net profit fell 71.4% YoY to Rs 130 million for the quarter ended June 2017, compared to a profit of Rs 455 million a year ago. Net sales declined 9.5% to Rs 3,396 million during the period as against Rs 3,754 million in April-June 2016.

For the year ended March 2016, Dishman Pharma reported 42.8% increase in net profit to Rs 1,710 million compared to net profit of Rs 1,198 million during FY15. Revenue of the company grew 0.5% to Rs 15,898 million during FY16.

The current Price to earnings ratio of Dishman Pharma, based on rolling 12 month earnings, stands at 59.2.


Equitymaster requests your view! Post a comment on "Dishman Pharma Gains 5%; BSE HEALTHCARE Index Down 0.1%". Click here!